Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy

References

• Abouzeid AH, Patel NR, Sarisozen C, Torchilin VP. (2014a). Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells. Pharm Res 31:1938–45.
   PubMed Web of Science ®Google Scholar
• Abouzeid AH, Patel NR, Torchilin VP. (2014b). Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int J Pharm 464:178.
   PubMed Web of Science ®Google Scholar
• Ana Catarina Pinto JNM, S. Simões (2011). Combination chemotherapy in cancer: principles, evaluation and drug delivery strategies. In: Ozdemir O, ed. Current cancer treatment – novel beyond conventional approaches. Istanbul: InTech, 693–714.
   Google Scholar
• Bajelan E, Haeri A, Vali AM, et al. (2012). Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J Pharm Pharm Sci 15:568–82.
   PubMed Web of Science ®Google Scholar
• Bonavida B, Khineche S, Huerta-Yepez S, Garbán H. (2006). Therapeutic potential of nitric oxide in cancer. Drug Resist Updat 9:157–73.
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–302.
   PubMed Web of Science ®Google Scholar
• Cai L, Xu G, Shi C, et al. (2014). Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials 37C:456–68.
   Google Scholar
• Chauhan G, Chopra V, Tyagi A, et al. (2016). “Gold nanoparticles composite-folic acid conjugated graphene oxide nanohybrids” for targeted chemo-thermal cancer ablation: in vitro screening and in vivo studies. Eur J Pharm Sci 96:351.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zhang S, et al. (2017). Cancer incidence and mortality in China, 2013. Cancer Lett 401:63–71.
   PubMed Web of Science ®Google Scholar
• Chen WH, Luo GF, Qiu WX, et al. (2016). Mesoporous silica-based versatile theranostic nanoplatform constructed by layer-by-layer assembly for excellent photodynamic/chemo therapy. Biomaterials 117:54.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang W, Huang Y, et al. (2015). Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor. Int J Pharm 488:44–58.
   PubMed Web of Science ®Google Scholar
• Chiang C-S, Hu S-H, Liao B-J, et al. (2014). Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds. Nanomed: Nanotechnol Biol Med 10:99–107.
   PubMed Web of Science ®Google Scholar
• Chou T-C. (2010). Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res 70:440–6.
   PubMed Web of Science ®Google Scholar
• Creixell M, Peppas NA. (2012). Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 7:367–79.
   PubMed Web of Science ®Google Scholar
• Dai X, Tan C. (2014). Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Deliv Rev 81:184–97.
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. (2012). PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161:505–22.
   PubMed Web of Science ®Google Scholar
• Devita VT, Serpick AA, Carbone PP. (1970). Combination chemotherapy in the treatment of advanced Hodgkins disease. Ann Int Med 73:881–95.
   PubMed Web of Science ®Google Scholar
• Duan X, Xiao J, Yin Q, et al. (2013). Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 7:5858–69.
   PubMed Web of Science ®Google Scholar
• Duong HH, Yung LY. (2013). Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment. Int J Pharm 454:486–95.
   PubMed Web of Science ®Google Scholar
• Eloy JO, Souza MCD, Petrilli R, et al. (2014). Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloid Surf B 123:345–63.
   PubMed Web of Science ®Google Scholar
• Espinosa E, Zamora P, Feliu J, González Barón M. (2003). Classification of anticancer drugs: a new system based on therapeutic targets. Cancer Treat Rev 29:515–23.
   PubMed Web of Science ®Google Scholar
• Feng T, Tian H, Xu C, et al. (2014). Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. Eur J Pharm Biopharm 88:1086–93.
   PubMed Web of Science ®Google Scholar
• Fox E, Bates SE. (2007). Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7:447–59.
   PubMed Web of Science ®Google Scholar
• Gao M, Xu Y, Qiu L. (2015). Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes. Int J Nanomedicine 10:6615.
   PubMed Web of Science ®Google Scholar
• Gilmore KA, Lampley MW, Boyer C, Harth E. (2015). Matrices for combined delivery of proteins and synthetic molecules. Adv Drug Deliv Rev 98:77–85.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. (1973). Drug entrapment in liposomes. FEBS Lett 36:292–6.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Ryman BE. (1960). Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Phys Rev 118:389–93.
   Google Scholar
• Guo S, Lin CM, Xu Z, et al. (2014). Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996–5009.
   PubMed Web of Science ®Google Scholar
• Guo Y, He W, Yang S, et al. (2017). Co-delivery of docetaxel and verapamil by reduction-sensitive PEG-PLGA-SS-DTX conjugate micelles to reverse the multi-drug resistance of breast cancer. Colloid Surf B 151:119–27.
   PubMed Web of Science ®Google Scholar
• Hao Y, Zhang B, Zheng C, et al. (2015). The tumor-targeting core-shell structured DTX-loaded PLGA@Au nanoparticles for chemo-photothermal therapy and X-ray imaging. J Control Release 220:545–55.
   PubMed Web of Science ®Google Scholar
• Hapala I. (1997). Breaking the barrier: methods for reversible permeabilization of cellular membranes. Crit Rev Biotechnol 17:105–22.
   PubMed Web of Science ®Google Scholar
• He C, Lu K, Liu D, Lin W. (2014). Nanoscale metal–organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J Am Chem Soc 136:5181–4.
   PubMed Web of Science ®Google Scholar
• He C, Tang Z, Tian H, Chen X. (2015). Co-delivery of chemotherapeutics and proteins for synergistic therapy. Adv Drug Deliv Rev 98:64–76.
   PubMed Web of Science ®Google Scholar
• Hofseth LJ, Hussain SP, Wogan GN, Harris CC. (2003). Nitric oxide in cancer and chemoprevention: This article is part of a series of reviews on “Nitric Oxide in Cancer Biology and Treatment”. The full list of papers may be found on the homepage of the journal. Free Radic Biol Med 34:955–68.
   PubMed Web of Science ®Google Scholar
• Hu CM, Aryal S, Zhang L. (2010). Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 1:323–34.
   PubMedGoogle Scholar
• Hu Q, Sun W, Wang C, Gu Z. (2016). Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev 98:19–34.
   PubMed Web of Science ®Google Scholar
• Huang YZ, Yu FQ, Park YS, et al. (2010). Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials 31:9086–91.
   PubMed Web of Science ®Google Scholar
• Jia HZ, Zhang W, Zhu JY, et al. (2015). Hyperbranched–hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy. J Control Release 216:9–17.
   PubMed Web of Science ®Google Scholar
• Jiang T, Mo R, Bellotti A, et al. (2014). Gel–liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy. Adv Funct Mater 24:2295–304.
   Web of Science ®Google Scholar
• Jin S, White E. (2007). Role of autophagy in cancer: management of metabolic stress. Autophagy 3:28–31.
   PubMed Web of Science ®Google Scholar
• Kemp JA, Shim MS, Heo CY, Kwon YJ. (2015). “Combo nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy”. Adv Drug Deliv Rev 98:3–18.
   PubMed Web of Science ®Google Scholar
• Kim J, Yung BC, Kim WJ, Chen X. (2017). Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy. J Control Release 263:223–30.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Tsukagoshi S, Sakurai Y. (1975). Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210. Gan 66:719–20.
   PubMedGoogle Scholar
• Kondo Y, Kanzawa T, Sawaya R, Kondo S. (2005). The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–34.
   PubMed Web of Science ®Google Scholar
• Lee AL, Wang Y, Cheng HY, et al. (2009). The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30:919–27.
   PubMed Web of Science ®Google Scholar
• Li JM, Wang YY, Zhao MX, et al. (2012). Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. Biomaterials 33:2780–90.
   PubMed Web of Science ®Google Scholar
• Li N, Zhang P, Huang C, et al. (2015a). Co-delivery of doxorubicin hydrochloride and verapamil hydrochloride by pH-sensitive polymersomes for the reversal of multidrug resistance. RSC Adv 5:77986–95.
   Web of Science ®Google Scholar
• Li Z, Li J, Huang J, et al. (2015b). Synthesis and characterization of pH-responsive copolypeptides vesicles for siRNA and chemotherapeutic drug co-delivery. Macromol Biosci 15:1497–506.
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Herndon JE, List MA, et al. (2005). Single-agent versus combination chemotherapy in advanced non–small-cell lung cancer: the cancer and leukemia group B (study 9730). Jco 3:190–6.
   Web of Science ®Google Scholar
• Limtrakul P. (2007). “Curcumin as chemosensitizer,” In: Aggarwal BB, Surh Y-J, Shishodia S, eds. The molecular targets and therapeutic uses of curcumin in health and disease. Boston, MA: Springer US, 269–300.
   Google Scholar
• Liu Y, Feng SS. (2011). The synergistic effect of herceptin and docetaxel in polylactide-D-α -tocopheryl polyethylene glycol succinate (PLA-TPGS) nanoparticles. J Control Release 152:e64–5.
   PubMed Web of Science ®Google Scholar
• Lv S, Tang Z, Li M, et al. (2014). Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials 35:6118–29.
   PubMed Web of Science ®Google Scholar
• Ma D, Zhou XY, Yang YF, et al. (2013). UV cross-linked redox-responsive hydrogels for co-delivery of hydrophilic and hydrophobic drugs. Sci Adv Mater 5:1307–15.
   Web of Science ®Google Scholar
• Mi Y, Zhao J, Feng SS. (2013). Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. J Control Release 169:185–92.
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. (2016). Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–89.
   PubMed Web of Science ®Google Scholar
• Misra R, Sahoo SK. (2011). Coformulation of doxorubicin and curcumin in poly (d,l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 8:852–66.
   PubMed Web of Science ®Google Scholar
• Mujokoro B, Adabi M, Sadroddiny E, Khosravani M. (2016). Nano-structures mediated co-delivery of therapeutic agents for glioblastoma treatment: a review. Mater Sci Eng C Mater Biol Appl 69:1092–102.
   PubMed Web of Science ®Google Scholar
• Nastiuk KL, Krolewski JJ. (2016). Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev 98:35–40.
   PubMed Web of Science ®Google Scholar
• Pan L, Liu J, He Q, et al. (2013). Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials 34:2719–30.
   PubMed Web of Science ®Google Scholar
• Patel NR, Rathi A, Mongayt D, Torchilin VP. (2011). Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 416:296–9.
   PubMed Web of Science ®Google Scholar
• Qin M, Lee Y-EK, Ray A, Kopelman R. (2014). Overcoming cancer multidrug resistance by codelivery of doxorubicin and verapamil with hydrogel nanoparticles. Macromol Biosci 14:1106–15.
   PubMed Web of Science ®Google Scholar
• Sarisozen C, Abouzeid AH, Torchilin VP. (2014). The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. Eur J Pharm Biopharm 88:539–50.
   PubMed Web of Science ®Google Scholar
• Sarisozen C, Vural I, Levchenko T, et al. (2012). Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Deliv 19:363–70.
   PubMed Web of Science ®Google Scholar
• Schilsky RL, Mcintyre OR, Holland JF, Frei E. (2006). A concise history of the cancer and leukemia group B. Clin Cancer Res 12:3553s–5s.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. (2012). Antibody therapy of cancer. Nat Rev Cancer 12:278–87.
   PubMed Web of Science ®Google Scholar
• Sharma V, Köllmer M, Szymusiak M, et al. (2014a). Toroidal-spiral particles for codelivery of anti-VEGFR-2 antibody and irinotecan: a potential implant to hinder recurrence of glioblastoma multiforme. Biomacromole 15:756–62.
   PubMed Web of Science ®Google Scholar
• Shen S, Tang H, Zhang X, et al. (2013). Targeting mesoporous silica-encapsulated gold nanorods for chemo-photothermal therapy with near-infrared radiation. Biomaterials 34:3150–8.
   PubMed Web of Science ®Google Scholar
• Shi C, Zhang Z, Shi J, et al. (2015). Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance. Int J Pharm 495:932–9.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. (2014). Cancer statistics, 2014. CA A Cancer Journal for Clinicians 64:9–29.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66:7–30.
   PubMed Web of Science ®Google Scholar
• Singh A, Dilnawaz F, Mewar S, et al. (2011). Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy. ACS Appl Mater Interfaces 3:842–56.
   PubMed Web of Science ®Google Scholar
• Sirova M, Horkova V, Etrych T, et al. (2017). Polymer donors of nitric oxide improve the treatment of experimental solid tumours with nanosized polymer therapeutics. J Drug Target 25:796–808.
   PubMed Web of Science ®Google Scholar
• Song Q, Tan S, Zhuang X, et al. (2014a). Nitric oxide releasing d-alpha-tocopheryl polyethylene glycol succinate for enhancing antitumor activity of doxorubicin. Mol Pharm 11:4118–29.
   PubMed Web of Science ®Google Scholar
• Song W, Tang Z, Zhang D, et al. (2014b). Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin. Biomaterials 35:3005–14.
   PubMed Web of Science ®Google Scholar
• Sriraman SK, Zhang Y, Luther E, et al. (2015). “Abstract 4416: Reversal of chemoresistance in ovarian cancer cells by the liposomal co-delivery of MDR inhibitors and paclitaxel”, in: Aacr Meeting), 4416.
   Google Scholar
• Sun L, Deng X, Yang X, et al. (2014). Co-delivery of doxorubicin and curcumin by polymeric micelles for improving antitumor efficacy on breast carcinoma. RSC Adv 4:46737–50.
   Web of Science ®Google Scholar
• Sun R, Shen S, Zhang Y-J, et al. (2016a). Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells. Biomaterials 103:44–55.
   PubMed Web of Science ®Google Scholar
• Sun Y, Kang C, Zhang A, et al. (2016b). Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance. Eur J BioMed Res 2:7.
   Google Scholar
• Suo A, Qian J, Zhang Y, et al. (2016). Comb-like amphiphilic polypeptide-based copolymer nanomicelles for co-delivery of doxorubicin and P-gp siRNA into MCF-7 cells. Mater Sci Eng C Mater Biol Appl 62:564–73.
   PubMed Web of Science ®Google Scholar
• Tang J, Zhang L, Gao H, et al. (2015). Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity. Drug Deliv 1–14.
   Web of Science ®Google Scholar
• Teo PY, Cheng W, Hedrick JL, Yang YY. (2016). Co-delivery of drugs and plasmid DNA for cancer therapy. Adv Drug Deliv Rev 98:41–63.
   PubMed Web of Science ®Google Scholar
• Wang C, Hu Q, Shen H-M. (2016a). Pharmacological inhibitors of autophagy as novel cancer therapeutic agents. Pharmacol Res 105:164–75.
   PubMed Web of Science ®Google Scholar
• Wang H, Agarwal P, Zhao S, et al. (2015a). Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials 72:74–89.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao Y, Wu Y, et al. (2011). Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32:8281–90.
   PubMed Web of Science ®Google Scholar
• Wang J, Ma W, Tu P. (2015b). Synergistically improved anti-tumor efficacy by co-delivery doxorubicin and curcumin polymeric micelles. Macromol Biosci 15:1252–61.
   PubMed Web of Science ®Google Scholar
• Wang M-R, Chiu S-J, Chou H-C, Hu T-M. (2015c). An efficient S-NO-polysilsesquioxane nano-platform for the co-delivery of nitric oxide and an anticancer drug. Chem Commun (Camb) 51:15649–52.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao S, Ye WH, et al. (2006a). Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 5:791–6.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang HY, Yang L, et al. (2016b). Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Sci Rep 6:25468.
   PubMed Web of Science ®Google Scholar
• Wang Y-Y, Zhang D-D, Kong Y-Y, et al. (2016c). CS/PAA@TPGS/PLGA nanoparticles with intracellular pH-sensitive sequential release for delivering drug to the nucleus of MDR cells. Colloid Surf B 145:716–27.
   PubMed Web of Science ®Google Scholar
• Weissig V, Pettinger TK, Murdock N. (2014). Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine 9:4357–73.
   PubMed Web of Science ®Google Scholar
• Wu J, Lu Y, Lee A, et al. (2007). Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10:350–7.
   PubMed Web of Science ®Google Scholar
• Xiao H, Li W, Qi R, et al. (2012a). Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy. J Control Release 163:304–14.
   PubMed Web of Science ®Google Scholar
• Xiao YL, Jaskula-Sztul R, Javadi A, et al. (2012b). Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 4:7185–93.
   PubMed Web of Science ®Google Scholar
• Xie X, Tao Q, Zou Y, et al. (2011). PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem 59:9280–9.
   PubMed Web of Science ®Google Scholar
• Xu B, Xia S, Wang F, et al. (2016a). Polymeric nanomedicine for combined gene/chemotherapy elicits enhanced tumor suppression. Mol Pharm 13:663–76.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhu X, Qiu L. (2016b). Polyphosphazene vesicles for co-delivery of doxorubicin and chloroquine with enhanced anticancer efficacy by drug resistance reversal. Int J Pharm 498:70.
   PubMed Web of Science ®Google Scholar
• Xu Q, Leong J, Qi YC, et al. (2013). Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 34:5149–62.
   PubMed Web of Science ®Google Scholar
• Xu Q, Xia Y, Wang CH, Pack DW. (2012). Monodisperse double-walled microspheres loaded with chitosan-p53 nanoparticles and doxorubicin for combined gene therapy and chemotherapy. J Control Release 163:130–5.
   PubMed Web of Science ®Google Scholar
• Yan J, Wang Y, Jia Y, et al. (2017). Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer. Biomed Pharmacother 88:374–83.
   PubMed Web of Science ®Google Scholar
• Yan T, Li D, Li J, (2016). Effective co-delivery of doxorubicin and curcumin using a glycyrrhetinic acid-modified chitosan-cystamine-poly(ε-caprolactone) copolymer micelle for combination cancer chemotherapy. Feng 145:526–38.
   Google Scholar
• Yao X, L, C, Chen X, Xie Z, et al. (2015). pH-responsive metallo-supramolecular nanogel for synergistic chemo-photodynamic therapy. Acta Biomater 25:162.
   PubMed Web of Science ®Google Scholar
• Yeo W, Mok TS, Zee B, et al. (2005). A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532–8.
   PubMed Web of Science ®Google Scholar
• Yi X, Lian X, Dong J, et al. (2015). Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers. Mol Pharm 12:4085.
   PubMed Web of Science ®Google Scholar
• Yin M, Tan S, Bao Y, Zhang Z. (2017). Enhanced tumor therapy via drug co-delivery and in situ vascular-promoting strategy. J Control Release 258:108–20.
   PubMed Web of Science ®Google Scholar
• Yu Z, Xiao CS, Li MQ, et al. (2014). Co-delivery of doxorubicin and paclitaxel with linear-dendritic block copolymer for enhanced anti-cancer efficacy. Sci China Chem 57:624–32.
   Web of Science ®Google Scholar
• Zhang D, Kong YY, Sun JH, et al. (2017a). Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine 12:2081–108.
   PubMed Web of Science ®Google Scholar
• Zhang F, Li M, Su Y, et al. (2016a). A dual-targeting drug co-delivery system for tumor chemo- and gene combined therapy. Mater Sci Eng C Mater Biol Appl 64:208–18.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li J, Shi Z, et al. (2017b). pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities. Acta Biomater 58:349–64.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Chen G, Liu X, Qian Q. (2007). Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res 17:89–99.
   PubMed Web of Science ®Google Scholar
• Zhang RX, Cai P, Zhang T, et al. (2016b). Polymer–lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin–mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomed Nanotechnol Biol Med 12:1279–90.
   PubMed Web of Science ®Google Scholar
• Zhang X, Dong Y, Zeng X, et al. (2014a). The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment. Biomaterials 35:1932–43.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ying Y, Xin L, et al. (2014b). Enhancing therapeutic effects of docetaxel-loaded dendritic copolymer nanoparticles by co-treatment with autophagy inhibitor on breast cancer. Theranostics 4:1085–95.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zeng X, Liang X, et al. (2014c). The chemotherapeutic potential of PEG-b-PLGA copolymer micelles that combine chloroquine as autophagy inhibitor and docetaxel as an anti-cancer drug. Biomaterials 35:9144–54.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiao C, Li M, et al. (2013). Co-delivery of 10-hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy. Macromol Biosci 13:584–94.
   PubMed Web of Science ®Google Scholar
• Zhao L, Yang G, Shi Y, et al. (2015). Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance. J Nanobiotechnol 13:1–10.
   PubMed Web of Science ®Google Scholar
• Zucker D, Andriyanov AV, Steiner A, et al. (2012). Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J Control Release 160:281–9.
   PubMed Web of Science ®Google Scholar